"GLP-1 receptor agonists and gastrointestinal side effects: Mechanisms and management." Diabetes Obes Metab , 2022
Metabolism 65 (5), 699713
GHK-Cu is commonly stacked with BPC-157 and TB-500 in a pre-mixed blend (GLOW, 5:1:1 ratio) or from separate vials
The last few years have seen a marked increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) used for managing type 2 diabetes and as a way to lose weight
Current Market Situation and Future Trends Current market situation At present, this tablet is mainly targeted at scientific research institutions and biotechnology companies, and is used for research in fields such as inflammatory bowel disease, multiple sclerosis, and wound healing.As it has not obtained drug approval, the market size is relatively small, but the demand is on the rise
More research is needed to confirm whether or not GLP-1 agonists have an impact on libido, and if so, whether these effects are reversible